A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24020989 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Maria Pia Adorni und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In tumors, the multi drug resistance phenomenon may occur through the efflux of chemotherapeutic drugs out of cancer cells, impeding their accumulation, and eventually reducing their toxicity. This process is mediated by transporters overexpressed in the plasma membranes of tumor cells, among which is the P-glycoprotein/multidrug resistance 1/ATP-binding cassette B1 (P-gp/MDR1/ABCB1). The aim of this study was to explore the effect of a new molecule, called AIF-1, on ABCB1 activity. In a cellular model of non-small cell lung cancer (NSCLC), AIF-1 significantly inhibited ABCB1 activity, which was evaluated by the fluorimetric measurement of the intracellular accumulation of calcein. AIF-1 also significantly increased the intracellular content of doxorubicin, which was evaluated by confocal microscopy and LC-MS/MS analysis. This effect translated to higher cytotoxicity of doxorubicin and reduced cellular proliferation. Finally, in a murine xenograft model, the tumor volume increased by 267% and 148% on average in mice treated with vehicle and doxorubicin alone, respectively. After the co-administration of doxorubicin with AIF-1, tumor volume increased by only 13.4%. In conclusion, these results suggest enhancement of the efficacy of the chemotherapeutic drug doxorubicin by AIF-1, laying the basis for the future development of new ABCB1 inhibitors for tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy.
- Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL-Italian Workers' Compensation Authority, Monte Porzio Catone, 00078 Rome, Italy.
- Department of Food and Drug, University of Parma, 43124 Parma, Italy.
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52056 Aachen, Germany.
ORCID-Profile: Maria Pia Adorni, Maricla Galetti, Silvia La Monica, Lisa Elviri, Ilaria Zanotti, Bianca Papotti, Delia Cavallo, Roberta Alfieri
Zitieren
APA
Adorni, M. P., Galetti, M., La Monica, S., Incerti, M., Ruffoni, A., Elviri, L., Zanotti, I., Papotti, B., Cavallo, D., Alfieri, R., Petronini, P. G., & Bernini, F. (2023). A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24020989
Vancouver
Adorni MP, Galetti M, La Monica S, Incerti M, Ruffoni A, Elviri L, et al. A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24020989
BibTeX
@article{Adorni2023,
author = {Adorni, Maria Pia and Galetti, Maricla and La Monica, Silvia and Incerti, Matteo and Ruffoni, Alessandro and Elviri, Lisa and Zanotti, Ilaria and Papotti, Bianca and Cavallo, Delia and Alfieri, Roberta and Petronini, Pier Giorgio and Bernini, Franco},
title = {A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24020989}
}
EUVIMED